RBM17 and ovarian carcinoma: Novel genes include RBM17, a splicing factor with enriched amplification in Triple-Negative Breast Cancer, a subtype shown to be selectively addicted to alternative splicing28, and SIRT3, a regulator of mitochondrial adaptive response to stress mechanisms that exhibits tumor suppressive functions in cancer29 and a promising therapeutic target as experimental findings show that the knockdown of SIRT3 enhanced migration and metastasis in ovarian cancer cells30.